^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    ALK (Anaplastic lymphoma kinase)

    i
    Other names: NBLST3, CD246, Anaplastic Lymphoma Kinase, Anaplastic Lymphoma Kinase (Ki-1), CD246 Antigen, Mutant Anaplastic Lymphoma Kinase, ALK, ALK Receptor Tyrosine Kinase, Anaplastic Lymphoma Receptor Tyrosine Kinase, ALK Tyrosine Kinase Receptor
    1d
    Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, Fred Hutchinson Cancer Center
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • EGFR mutation • MSI-H/dMMR • ALK rearrangement
    |
    Opdivo (nivolumab) • ABP 206 (nivolumab biosimilar)
    1d
    POLARIX: A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P3, N=1000, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed
    Trial completion
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6)
    |
    ALK positive • CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Polivy (polatuzumab vedotin-piiq)
    2d
    CD45BE-HSPC + CART-45 Cells (clinicaltrials.gov)
    P1, N=42, Not yet recruiting, University of Pennsylvania | Trial completion date: Apr 2043 --> Jul 2051 | Initiation date: Apr 2026 --> Jul 2026 | Trial primary completion date: Apr 2043 --> Jul 2051
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • CD8 (cluster of differentiation 8) • BCL6 (B-cell CLL/lymphoma 6) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C)
    2d
    Uterine leiomyoma-like inflammatory myofibroblastic tumor: two case reports and literature review. (PubMed, Front Oncol)
    Fluorescence in situ hybridization (FISH) confirmed the presence of ALK gene breaks. A comprehensive understanding of these IMTs with leiomyoma-like features and accurate diagnosis are essential for effective patient treatment and prognosis.
    Journal
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive
    2d
    Gene Fusions in Melanocytic Lesions: An Updated Comprehensive Review. (PubMed, J Pathol Transl Med)
    Early clinical evidence of TRK, ALK, and ROS1 inhibitor efficacy underscores the translational promise of fusion testing and opens avenues for personalized therapy. This review synthesizes current knowledge on the genomics, histopathology, diagnosis, and therapeutic implications of fusion-driven melanocytic neoplasms, highlighting consensus points and remaining controversies.
    Journal
    |
    BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • MAP3K8 (Mitogen-Activated Protein Kinase Kinase Kinase 8)
    |
    ALK fusion • ROS1 fusion
    3d
    Multidisciplinary Treatment of Stage III ALK+ NSCLC With Neoadjuvant Alectinib and Chemotherapy (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, Wen-zhao ZHONG
    New P2 trial
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK fusion
    |
    Alecensa (alectinib) • Piqray (alpelisib)
    3d
    EVOKE-01: Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P3, N=603, Active, not recruiting, Gilead Sciences | Trial completion date: Jan 2026 --> Jan 2027
    Trial completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    docetaxel • Trodelvy (sacituzumab govitecan-hziy)
    3d
    Renal cell carcinoma with a novel RAB1A::ALK fusion: expanding the molecular spectrum of ALK-rearranged RCC. (PubMed, Virchows Arch)
    This report describes the clinicopathological and molecular features of the tumor, with a particular focus on the characterization of the RAB1A gene and its documented impact on carcinogenesis and prognosis across several solid malignancies. Our findings expand the molecular spectrum of ALK-RCC and emphasize the role of comprehensive molecular profiling in uropathology.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • CA9 (Carbonic anhydrase 9) • RAB1A (RAB1A, Member RAS Oncogene Family)
    |
    ALK rearrangement • ALK fusion
    3d
    Individualized duration of adjuvant alectinib therapy and rechallenge efficacy in ALK-positive non-small cell lung cancer: a case report. (PubMed, Front Med (Lausanne))
    Further research is needed to validate these approaches in larger cohorts. Furthermore, the favorable response to alectinib rechallenge observed in this case suggests that rechallenge therapy may offer a potential value in managing post-adjuvant recurrence, which warrants further investigation.
    Journal
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive • ALK rearrangement
    |
    Alecensa (alectinib)
    3d
    Potential of Minimal Residual Disease in Guiding Adjuvant Therapy Decisions in Non-Small Cell Lung Cancer. (PubMed, JCO Precis Oncol)
    ctDNA-based MRD stratifies prognosis after curative resection in NSCLC, with MRD negativity indicating limited benefit from treatment in selected patients and ctDNA clearance reflecting improved outcomes. These findings support the clinical utility of MRD-guided adjuvant treatment strategies.
    Journal • IO biomarker • Minimal residual disease
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • EGFR wild-type • ALK wild-type
    4d
    A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P3, N=68, Active, not recruiting, Hoffmann-La Roche | Trial primary completion date: Dec 2026 --> Jun 2030
    Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ALK positive • ALK fusion • ROS1 fusion • ROS1 positive
    |
    PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay
    |
    Imfinzi (durvalumab) • Rozlytrek (entrectinib) • Alecensa (alectinib)